Following sharp decline during COVID-19, RSV-positive acute respiratory infection reemerged during summer 2021, and is linked to lower QOL<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Jan. 23, 2023 (HealthDay News) — The burden of respiratory syncytial virus (RSV)-positive acute respiratory infection (ARI) in older adults was considerable before COVID-19 and is associated with lower quality of life (QOL), according to a study published online Jan. 20 in JAMA Network Open<\/em>.<\/p>\n Young J. Juhn, M.D., M.P.H., from the Mayo Clinic in Rochester, Minnesota, and colleagues conducted a community-based cohort study that followed 2,325 adults aged 50 years or older for two RSV seasons from 2019 to 2021 to examine the incidence of RSV-positive ARI before and during the COVID-19 pandemic.<\/p>\n The researchers found that the incidence rate of RSV-positive ARI was 48.6 per 1,000 person-years before the pandemic, with an attack rate of 2.50 percent. During the COVID-19 pandemic RSV season, there were no RSV-positive ARI cases identified. During the summer of 2021, the incidence was 10.2 per 1,000 person-years and the attack rate was 0.42 percent. Participants with RSV-positive ARI reported a significantly lower quality-of-life adjusted mean difference within two to four weeks after RSV-positive ARI compared with matched RSV-negative ARI, based on prepandemic RSV season results. Those with RSV-positive versus RSV-negative ARI had lower quality of life at six to seven and at 12 to 13 months after RSV-positive ARI.<\/p>\n “RSV-positive ARI was associated with significant long-term impacts on health-related QOL beyond the acute infection in adults over 50,” the authors write. “An effective RSV vaccine might be an important measure to mitigate the impact of RSV-positive ARI, especially in older adults.”<\/p>\n Several authors disclosed financial ties to biopharmaceutical companies, including GlaxoSmithKline, which funded the study.<\/p>\n